PDI (PDII) Extends Sales Contract with Top 5 Pharma Company; Expects $33M in Revs
Tweet Send to a Friend
PDI, Inc. (NASDAQ: PDII) today announced the extension of its contract sales engagement with a Top 5 pharmaceutical company. The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
